Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer
2018 · OncoImmunology · 60 citations
https://doi.org/10.1080/2162402x.2018.1471440
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
137
Papers
3.0K
Citations
27
h-index
50
i10-index
Roy Xiao is an academic researcher from Massachusetts Eye and Ear Infirmary. The author has contributed to research in topics: Healthcare Policy and Management & Head and Neck Cancer Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 27, co-authored 117 publications.
ORCID: 0000-0003-4459-0746https://doi.org/10.1080/2162402x.2018.1471440
https://doi.org/10.1002/hed.25873
https://doi.org/10.1007/s00266-024-04316-3
Click to start Chat